The Role of Phosphodiesterase Enzymes in Allergy and Asthma

Advances in Pharmacology

Volumn 44, Issue C, 1998, Pages 33-89

  Spina, D ^a,b,c   Landells, L J ^a,b,c   Page, C P ^a,b,c  

^a The Sackler Institute of Pulmonary Pharmacology

^b Department of Respiratory Medicine ^*

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE;

ANIMAL; ASTHMA; CLASSIFICATION; DISEASE MODEL; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; INFLAMMATION; LEUKOCYTE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ASTHMA; DISEASE MODELS, ANIMAL; HUMANS; HYPERSENSITIVITY, IMMEDIATE; INFLAMMATION; LEUKOCYTES; PHOSPHORIC DIESTER HYDROLASES;

EID: 0031601540     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60125-8     Document Type: Chapter

References (342)

1. Alfonso A., Estevez M., Louzao M.C., Vieytes M.R., and Botana L.M. Determination of phosphodiesterase activity in rat mast cells using the fluorescent cAMP analogue anthraniloyl cAMP. Cell. Signal. 7 (1995) 513-518
2. Ali S., Mustafa S.J., and Metzger W.J. Modification of allergen-induced airway obstruction and bronchial hyperresponsiveness in the allergic rabbit by theophylline aerosol. Agents Actions 37 (1992) 168-170
3. Aloui R., Gormand F., Prigent A.F., PerrinFayolle M., and Pacheco Y. Increased respiratory burst and phosphodiesterase activity in alveolar eosinophils in chronic eosinophilic pneumonia. Eur. Respir. J. 9 (1996) 377-379
4. Alston W.C., Patel K.R., and Kerr J.W. Response of leucocyte adenyl cyclase to isoprenaline and effect of alpha-blocking drugs in extrinsic bronchial asthma. BMJ 1 (1974) 90-93
5. Alvarez R., Sette C., Yang D., Eglen R.M., Wilhelm R., Shelton E.R., and Conti M. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol. Pharmacol. 48 (1995) 616-622
6. Alves A.C., Pires A.L.A., Cruz H.N., Serra M.F., Diaz B.L., Cordeiro R.S.B., Lagente V., Martins M.A., and de Silva P.M.R. Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro. Eur. J. Pharmacol. 312 (1996) 89-96
7. Anastassiou E.D., Paliogianni F., Balow J.P., Yamada H., and Boumpas D.T. Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R alpha gene expression at multiple levels. J. Immunol. 148 (1992) 2845-2852
8. Archer C.B., Morley J., and MacDonald D.M. Impaired lymphocyte cyclic adenosine monophosphate responses in atopic eczema. Br. J. Dermatol. 109 (1983) 559-564
9. Averill L.E., Stein R.L., and Kammer G.M. Control of human T-lymphocyte interleukin-2 production by a cAMP-dependent pathway. Cell. Immunol. 115 (1988) 88-99
10. Bachelet M., Vincent D., Havet N., Marrash Chahla R., Pradalier A., Dry J., and Vargaftig B.B. Reduced responsiveness of adenylate cyclase in alveolar macrophages from patients with asthma. J. Allergy Clin. Immunol. 88 (1991) 322-328
11. Baer R.L. Papaverine therapy in atopic dermatitis. J. Am. Acad. Dermatol. 13 (1985) 806-808
12. Baixeras E., GarciaLozano E., and Martinez A.C. Decrease in cAMP levels promoted by CD48-CD2 interaction correlates with inhibition of apoptosis in B cells. Scand. J. Immunol. 43 (1996) 406-412
13. Baker A.J., and Fuller R.W. Effect of cyclic adenosine monophosphate, 5'-(N-ethylcarboxyamido)-adenosine and methylxanthines on the release of thromboxane and lysosomal enzymes from human alveolar macrophages and peripheral blood monocytes in vitro. Eur. J. Pharmacol. 211 (1992) 157-161
14. Banner K.H., Marchini F., Buschi A., Moriggi E., Semeraro C., and Page C.P. The effect of selective phosphodiesterase inhibitors in comparison with other anti-asthma drugs on allergen-induced eosinophilia in guinea-pig airways. Pulm. Pharmacol. 8 (1995) 37-42
15. Banner K.H., and Page C.P. Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitized guinea-pigs. Br. J. Pharmacol. 114 (1995) 93-98
16. Banner K.H., Roberts N.M., and Page C.P. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis. Br. J. Pharmacol. 116 (1996) 3169-3174
17. Barnette M.S., Bartus J.O., Burman M., Christensen S.B., Cieslinski L.B., Esser K.M., Prabhakar U.S., Rush J.A., and Torphy T.J. Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding. Biochem. Pharmacol. 51 (1996) 949-956
18. Barnette M.S., Grous M., Cieslinski L.B., Burman M., Christensen S.B., and Torphy T.J. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: Correlation between function and interaction with a high-affinity rolipram binding site. J. Pharmacol. Exp. Ther. 273 (1995) 1396-1402
19. Barnette M.S., Manning C.D., Cieslinski L.B., Burman M., Christensen S.B., and Torphy T.J. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. J. Pharmacol. Exp. Ther. 273 (1995) 674-679
20. Beavo J.A. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol. Rev. 75 (1995) 725-748
21. Beavo J.A., and Reifsnyder D.H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci. 11 (1990) 150-155
22. Berth Jones J., and Graham Brown R.A. Failure of papaverine to reduce pruritus in atopic dermatitis: A double-blind, placebo-controlled cross-over study. Br. J. Dermatol. 122 (1990) 553-557
23. Bessler H., Gilgal R., Djaldetti M., and Zahavi I. Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J. Leukoc. Biol. 40 (1986) 747-754
24. Betz M., and Fox B.S. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J. Immunol. 146 (1991) 108-113
25. Beusenberg F.D., Hoogsteden H.C., Bonta I.L., and van Amsterdam J.G. Cyclic AMP enhancing drugs modulate eicosanoid release from human alveolar macrophages. Life Sci. 54 (1994) 1269-1274
26. Bolger G.B. Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: A diverse family of regulatory enzymes. Cell. Signal. 6 (1994) 851-859
27. Boschetto P., Roberts N.M., Rogers D.F., and Barnes P.J. Effect of antiasthma drugs on microvascular leakage in guinea pig airways. Am. Rev. Respir. Dis. 139 (1989) 416-421
28. Brenner M., Berkowitz R., Marshall N., and Strunk R.C. Need for theophylline in severe steroid-requiring asthmatics. Clin. Allergy 18 (1988) 143-150
29. Brooks S.M., McGowan K., Bernstein I.L., Altenau P., and Peagler J. Relationship between numbers of beta adrenergic receptors in lymphocytes and disease severity in asthma. J. Allergy Clin. Immunol. 63 (1979) 401-406
30. Bruynzeel P.L., van den Berg W., and Leferink J.G. The bronchial tree and the beta-adrenergic system. Eur. J. Respir. Dis. Suppl. 121 (1982) 64-71
31. Burns F., Stevens P.A., and Pyne N.J. The identification of apparently novel cyclic AMP and cyclic GMP phosphodiesterase activities in guinea-pig tracheal smooth muscle. Br. J. Pharmacol. 113 (1994) 3-4
32. Busse W.W., and Anderson C.L. The granulocyte response to the phosphodiesterase inhibitor RO 20-1724 in asthma. J. Allergy Clin. Immunol. 67 (1981) 70-74
33. Butler J.M., Chan S.C., Stevens S., and Hanifin J.M. Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. J. Allergy Clin. Immunol. 71 (1983) 490-497
34. Casnocha S.A., Eskin S.G., Hall E.R., and McIntire L.V. Permeability of human endothelial monolayers: Effect of vasoactive agonists and cAMP. J. Appl. Physiol. 67 (1989) 1997-2005
35. Chan S.C., Brown M.A., Willcox T.M., Li S.H., Stevens S.R., Tara D., and Hanifin J.M. Abnormal IL-4 gene expression by atopic dermatitis T lymphocytes is reflected in altered nuclear protein interactions with IL-4 transcriptional regulatory element. J. Invest. Dermatol. 106 (1996) 1131-1136
36. Chan S.C., and Hanifin J.M. Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes. J. Lab. Clin. Med. 121 (1993) 44-51
37. Chan S.C., Hanifin J.M., Holden C.A., Thompson W.J., and Hirshman C.A. Elevated leukocyte phosphodiesterase as a basis for depressed cyclic adenosine monophosphate responses in the Basenji greyhound dog model of asthma. J. Allergy Clin. Immunol. 76 (1985) 148-158
38. Chan S.C., Henderson Jr. W.R., Shi-Hua L., and Hanifin J.M. Prostaglandin E2 control of T cell cytokine production is functionally related to the reduced lymphocyte proliferation in atopic dermatitis. J. Allergy Clin. Immunol. 97 (1996) 85-94
39. Chan S.C., Kim J.W., Henderson Jr. W.R., and Hanifin J.M. Altered prostaglandin E2 regulation of cytokine production in atopic dermatitis. J. Immunol. 151 (1993) 3345-3352
40. Chan S.C., Li S.H., and Hanifin J.M. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J. Invest. Dermatol. 100 (1993) 681-684
41. Chan S.C., Reifsnyder D., Beavo J.A., and Hanifin J.M. Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J. Allergy Clin. Immunol. 91 (1993) 1179-1188
42. Charbonneau H., Prusti R.K., LeTrong H., Sonnenburg W.K., Mullaney P.J., Walsh K.A., and Beavo J.A. Identification of a noncatalytic cGMP-binding domain conserved in both the cGMP-stimulated and photoreceptor cyclic nucleotide phosphodiesterases. Proc. Natl. Acad. Sci. USA 87 (1990) 288-292
43. Cockcroft D.W., Murdock K.Y., Gore B.P., O'Byrne P.M., and Manning P. Theophylline does not inhibit allergen-induced increase in airway responsiveness to metha-choline. J. Allergy Clin. Immunol. 83 (1989) 913-920
44. Cohan V.L., Showell H.J., Fisher D.A., Pazoles C.J., Watson J.W., Turner C.R., and Cheng J.B. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633. J. Pharmacol. Exp. Ther. 278 (1996) 1356-1361
45. Columbo M., Botana L.M., Horowitz E.M., Lichtenstein L.M., and MacGlashan Jr. D.W. Studies of the intracellular Ca2+ levels in human adult skin mast cells activated by the ligand for the human c-kit receptor and anti-IgE. Biochem. Pharmacol. 47 (1994) 2137-2145
46. Columbo M., Horowitz E.M., McKenzie White J., Kagey Sobotka A., and Lichtenstein L.M. Pharmacologic control of histamine release from human basophils induced by platelet-activating factor. Int. Arch. Allergy Immunol. 102 (1993) 383-390
47. Condino Neto A., Vilela M.M., Cambiucci E.C., Ribeiro J.D., Guglielmi A.A., Magna L.A., and De Nucci G. Theophylline therapy inhibits neutrophil and mononuclear cell chemotaxis from chronic asthmatic children. Br. J. Clin. Pharmacol. 32 (1991) 557-561
48. Conti M., Jin S.L., Monaco L., Repaske D.R., and Swinnen J.V. Hormonal regulation of cyclic nucleotide phosphodiesterases. Endocr. Rev. 12 (1991) 218-234
49. Conti M., Nemoz G., Sette C., and Vicini E. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr. Rev. 16 (1995) 370-389
50. Cooper K.D., Kang K., Chan S.C., and Hanifin J.M. Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro. J. Invest. Dermatol. 84 (1985) 477-482
51. Coqueret O., Dugas B., Mencia Huerta J.M., and Braquet P. Regulation of IgE production from human mononuclear cells by beta 2-adrenoceptor agonists. Clin. Exp. Allergy 25 (1995) 304-311
52. Cortijo J., Bou J., Beleta J., Cardelus I., Llenas J., Morcillo E., and Gristwood R.W. Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus. Br. J. Pharmacol. 108 (1993) 562-568
53. Coulson I.H., Duncan S.N., and Holden C.A. Peripheral blood mononuclear leukocyte cyclic adenosine monophosphate specific phosphodiesterase activity in childhood atopic dermatitis. Br. J. Dermatol. 120 (1989) 607-612
54. Crocker I.C., Townley R.G., and Khan M.M. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. Immunopharmacology 31 (1996) 223-235
55. de Boer J., Philpott A.J., van Amsterdam R.G., Shahid M., Zaagsma J., and Nicholson C.D. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: Biochemical and pharmacological analysis using selective inhibitors. Br. J. Pharmacol. 106 (1992) 1028-1034
56. Deisher T.A., Garcia I., and Harlan J.M. Cytokine-induced adhesion molecule expression on human umbilical vein endothelial cells is not regulated by cyclic adenosine monophosphate accumulation. Life Sci. 53 (1993) 365-370
57. Dent G., Giembycz M.A., Evans P.M., Rabe K.F., and Barnes P.J. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: Interaction with the beta adrenoceptor agonist albuterol. J. Pharmacol. Exp. Ther. 271 (1994) 1167-1174
58. Dent G., Giembycz M.A., Rabe K.F., and Barnes P.J. Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors. Br. J. Pharmacol. 103 (1991) 1339-1346
59. Derian C.K., Santulli R.J., Rao P.E., Solomon H.F., and Barrett J.A. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J. Immunol. 154 (1995) 308-317
60. DiSanto M.E., Glaser K.B., and Heaslip R.J. Phospholipid regulation of a cyclic AMP-specific phosphodiesterase (PDE4) from U937 cells. Cell. Signal. 7 (1995) 827-835
61. Eckly A.E., and Lugnier C. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway. Br. J. Pharmacol. 113 (1994) 445-450
62. Elliott K.R., and Leonard E.J. Interactions of formylmethionyl-leucyl-phenylalanine, adenosine, and phosphodiesterase inhibitors in human monocytes. Effects on superoxide release, inositol phosphates and cAMP. FEBS Lett. 254 (1989) 94-98
63. Elwood W., Sun J., Barnes P.J., Giembycz M.A., and Chung K.F. Inhibition of allergen-induced lung eosinophilia by type-III and combined type III- and IV-selective phosphodiesterase inhibitors in brown-Norway rats. Inflamm. Res. 44 (1995) 83-86
64. Endres S., Fulle H.J., Sinha B., Stoll D., Dinarello C.A., Gerzer R., and Weber P.C. Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factoralpha and interleukin-1 beta by human mononuclear cells. Immunology 72 (1991) 56-60
65. Engels P., Fichtel K., and Lubbert H. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett. 350 (1994) 291-295
66. Erjefalt I., and Persson C.G. Pharmacologic control of plasma exudation into tracheobronchial airways. Am. Rev. Respir. Dis. 143 (1991) 1008-1014
67. Essayan D.M., Huang S.K., Kagey Sobotka A., and Lichtenstein L.M. Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral blood mononuclear cells. Am. J. Respir. Cell Mol. Biol. 13 (1995) 692-702
68. Essayan D.M., Huang S.K., Undem B.J., Kagey Sobotka A., and Lichtenstein L.M. Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J. Immunol. 153 (1994) 3408-3416
69. Ferretti M.E., Spisani S., Pareschi M.C., Buzzi M., Cavallaro R., Traniello S., Reali E., Torrini I., Paradisi M.P., Zecchini G.P., et al. Two new formylated peptides able to activate chemotaxis and respiratory burst selectively as tools for studying human neutrophil responses. Cell. Signal. 6 (1994) 91-101
70. Fink G., Mittelman M., Shohat B., and Spitzer S.A. Theophylline-induced alterations in cellular immunity in asthmatic patients. Clin. Allergy 17 (1987) 313-316
71. Finnerty J.P., Lee C., Wilson S., Madden J., Djukanovic R., and Holgate S.T. Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: A placebo-controlled parallel group study. Eur. Respir. J. 9 (1996) 1672-1677
72. Foissier L., Lonchampt M., Coge F., and Canet E. In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor. J. Pharmacol. Exp. Ther. 278 (1996) 1484-1490
73. Fonteh A.N., Winkler J.D., Torphy T.J., Heravi J., Undem B.J., and Chilton F.H. Influence of isoproterenol and phosphodiesterase inhibitors on platelet-activating factor biosynthesis in the human neutrophil. J. Immunol. 151 (1993) 339-350
74. Francis S.H., and Corbin J.D. Purification of cGMP-binding protein phosphodiesterase from rat lung. Methods Enzymol. 159 (1988) 722-729
75. Frossard N., Landry Y., Pauli G., and Ruckstuhl M. Effects of cyclic AMP- and cyclic GMP-phosphodiesterase inhibitors on immunological release of histamine and on lung contraction. Br. J. Pharmacol. 73 (1981) 933-938
76. Fuller R.W., O'Malley G., Baker A.J., and MacDermot J. Human alveolar macrophage activation: Inhibition by forskolin but not beta-adrenoceptor stimulation or phosphodiesterase inhibition. Pulm. Pharmacol. 1 (1988) 101-106
77. Gardette J., Margelin D., Maziere J.C., Bertrand J., and Picard J. Effect of dibutyryl cyclic AMP and theophylline on lipoprotein lipase secretion by human monocyte-derived macrophages. FEBS Lett. 225 (1987) 178-182
78. Geist C., Schneider J., and Zimmer O. Effect of the lipoxygenase inhibitor N-hydroxy-N-(6-methoxy-3, 4-dihydro-2-naphthylmethyl)urea on bronchoconstriction and lung vascular permeability in anaphylactic guinea pigs. Arzneimittelforschung Drug Res. 45 (1995) 155-158
79. Giembycz M.A. Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma?. Biochem. Pharmacol. 43 (1992) 2041-2051
80. Giembycz M.A. Phosphodiesterase 4 and tolerance to β2-adrenoceptor agonists in asthma. Trends Pharmacol. Sci. 17 (1996) 331-336
81. + T-lymphocytes: Role in regulating proliferation and the biosynthesis of interleukin-2. Br. J. Pharmacol. 118 (1996) 1945-1958
82. Gillespie E., Valentine M.D., and Lichtenstein L.M. Cyclic AMP metabolism in asthma: Studies with leukocytes and lymphocytes. J. Allergy Clin. Immunol. 53 (1974) 27-33
83. Giustina T.A., Chan S.C., Thiel M.L., Baker J.W., and Hanifin J.M. Increased leukocyte sensitivity to phosphodiesterase inhibitors in atopic dermatitis: Tachyphylaxis after theophylline therapy. J. Allergy Clin. Immunol. 74 (1984) 252-257
84. Godfrey R.W., Manzi R.M., Gennaro D.E., and Hoffstein S.T. Phospholipid and arachidonic acid metabolism in zymosan-stimulated human monocytes: Modulation by cAMP. J. Cell. Physiol. 131 (1987) 384-392
85. Godfrey R.W., Manzi R.M., Jensen B.D., and Hoffstein S.T. FMLP-induced arachidonic acid release, phospholipid metabolism, and calcium mobilization in human monocytes. Regulation by cyclic AMP. Inflammation 12 (1988) 223-230
86. Goldie R.G., Spina D., Henry P.J., Lulich K.M., and Paterson J.W. In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta-adrenoceptor agonists and theophylline. Br. J. Clin. Pharmacol. 22 (1986) 669-676
87. Gonzalez M.C., Diaz P., Galleguillos F.R., Ancic P., Cromwell O., and Kay A.B. Allergen-induced recruitment of bronchoalveolar helper (OKT4) and suppressor (OKT8) T-cells in asthma. Relative increases in OKT8 cells in single early responders compared with those in late-phase responders. Am. Rev. Respir. Dis. 136 (1987) 600-604
88. Gozzard N., El-Hashim A., Herd C.M., Blake S.M., Holbrook M., Hughes B., Higgs G.A., and Page C.P. Effect of the glucocorticosteroid budesonide and a novel phosphodiesterase type 4 inhibitor CDP840 on antigen-induced airway responses in neonatally immunised rabbits. Br. J. Pharmacol. 118 (1996) 1201-1208
89. Gozzard N., Herd C.M., Blake S.M., Holbrook M., Hughes B., Higgs G.A., and Page C.P. Effects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbits. Br. J. Pharmacol. 117 (1996) 1405-1412
90. Greten T.F., Sinha B., Haslberger C., Eigler A., and Endres S. Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-alpha synthesis. Eur. J. Pharmacol. 299 (1996) 229-233
91. Grewe M., Walther S., Gyufko K., Czech W., Schopf E., and Krutmann J. Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J. Invest. Dermatol. 105 (1995) 407-410
92. Grewe S.R., Chan S.C., and Hanifin J.M. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: A possible mechanism for cyclic AMP-agonist hyporesponsiveness. J. Allergy Clin. Immunol. 70 (1982) 452-457
93. Gristwood R.W., Llupia J., Fernandez A.G., and Berga P. Effects of theophylline compared with prednisolone on late phase airway leukocyte infiltration in guinea pigs. Int. Arch. Allergy Appl. Immunol. 94 (1991) 293-294
94. Griswold D.E., Webb E.F., Breton J., White J.R., Marshall P.J., and Torphy T.J. Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response. Inflammation 17 (1993) 333-344
95. Guillou P.J., Ramsden C., Kerr M., Davison A.M., and Giles G.R. A prospective controlled clinical trial of aminophylline as an adjunctive immunosuppressive agent. Transplant. Proc. 16 (1984) 1218-1220
96. Hadjokas N.E., Crowley J.J., Bayer C.R., and Nielson C.P. beta-Adrenergic regulation of the eosinophil respiratory burst as detected by lucigenin-dependent luminescence. J. Allergy Clin. Immunol. 95 (1995) 735-741
97. Haen E., Hauck R., Emslander H.P., Langenmayer I., Liebl B., Schopohl J., Remien J., and Fruhmann G. Nocturnal asthma. Beta 2-adrenoceptors on peripheral mononuclear leukocytes, cAMP- and cortisol-plasma concentrations. Chest 100 (1991) 1239-1245
98. Hall I.P. Isoenzyme selective phosphodiesterase inhibitors: Potential clinical uses. Br. J. Clin. Pharmacol. 35 (1993) 1-7
99. Hallsworth M.P., Giembycz M.A., Barnes P.J., and Lee T.H. Cyclic AMP-elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM-CSF. Br. J. Pharmacol. 117 (1996) 79-86
100. Hamid Q., Boguniewicz M., and Leung D.Y. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J. Clin. Invest. 94 (1994) 870-876
101. Hancock W.W., Pleau M.E., and Kobzik L. Recombinant granulocyte-macrophage colony-stimulating factor down-regulates expression of IL-2 receptor on human mononuclear phagocytes by induction of prostaglandin E. J. Immunol. 140 (1988) 3021-3025
102. Hanifin J.M., and Chan S.C. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J. Invest. Dermatol. 105 (1995) 84S-88S
103. Hanifin J.M., Chan S.C., Cheng J.B., Tofte S.J., Henderson Jr. W.R., Kirby D.S., and Weiner E.S. Type 4 phosphodiesterase inhibitors have clinical and in vitro antiinflammatory effects in atopic dermatitis. J. Invest. Dermatol. 107 (1996) 51-56
104. Harbinson P.L., MacLeod D., Hawksworth R., O'Toole S., Sullivan P.J., Heath P., Kilfeather S., Page C.P., Costello J., Holgate S.T., and Lee T.H. The effect of a novel orally active selective PDE4 isoenzyme inhibitor CDP840 on allergen-induced responses in asthmatic subjects. Eur. Respir. J. 10 (1997) 1008-1014
105. Harris A.L., Connell M.J., Ferguson E.W., Wallace A.M., Gordon R.J., Pagani E.D., and Silver P.J. Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig. J. Pharmacol. Exp. Ther. 251 (1989) 199-206
106. Harvath L., Robbins J.D., Russell A.A., and Seamon K.B. cAMP and human neutrophil chemotaxis. Elevation of cAMP differentially affects chemotactic responsiveness. J. Immunol. 146 (1991) 224-232
107. Hatzelmann A., Tenor H., and Schudt C. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br. J. Pharmacol. 114 (1995) 821-831
108. Heinkelein M., Schneider-Schaulies J., Walker B.D., and Jassoy C. Inhibition of cytotoxicity and cytokine release of CD8+ HIV-specific cytotoxic T lymphocytes by pentoxifylline. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10 (1995) 417-424
109. Hendeles L., Harman E., Huang D., O'Brien R., Blake K., and Delafuente J. Theophylline attenuation of airway responses to allergen: Comparison with cromolyn metered-dose inhaler. J. Allergy Clin. Immunol. 95 (1995) 505-514
110. Heskel N.S., Chan S.C., Thiel M.L., Stevens S.R., Casperson L.S., and Hanifin J.M. Elevated umbilical cord blood leukocyte cyclic adenosine monophosphate-phosphodiesterase activity in children with atopic parents. J. Am. Acad. Dermatol. 11 (1984) 422-426
111. Hichami A., Boichot E., Germain N., Legrand A., Moodley I., and Lagente V. Involvement of cyclic AMP in the effects of phosphodiesterase IV inhibitors on arachidonate release from mononuclear cells. Eur. J. Pharmacol. 291 (1995) 91-97
112. Hilkens C.M., Vermeulen H., van Neerven R.J., Snijdewint F.G., Wierenga E.A., and Kapsenberg M.L. Differential modulation of T helper type 1 (Th1) and T helper type 2 (Th2) cytokine secretion by prostaglandin E2 critically depends on interleukin-2. Eur. J. Immunol. 25 (1995) 59-63
113. Hirshman C.A., Leu D.B., Austin D.R., Chan S.C., Veith L., and Hanifin J.M. Elevated mononuclear leukocyte phosphodiesterase in allergic dogs with and without airway hyperresponsiveness. J. Allergy Clin. Immunol. 79 (1987) 46-53
114. Holbrook M., Gozzard N., James T., Higgs G., and Hughes B. Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor. Br. J. Pharmacol. 118 (1996) 1192-1200
115. Holden C.A., Chan S.C., and Hanifin J.M. Monocyte localization of elevated cAMP phosphodiesterase activity in atopic dermatitis. J. Invest. Dermatol. 87 (1986) 372-376
116. Holden C.A., and Yuen C.T. Response of mononuclear leukocyte cyclic adenosine monophosphate-phosphodiesterase activity to treatment with topical fluorinated steroid ointment in atopic dermatitis. J. Am. Acad. Dermatol. 21 (1989) 69-74
117. Hossain M., Okubo Y., and Sekiguchi M. Effects of various drugs (staurosporine, herbimycin A, ketotifen, theophylline, FK506 and cyclosporin A) on eosinophil viability. Arerugi 43 (1994) 711-717
118. Hoting E., Reiss J., and Schulz K.H. [Papaverin-Effective in therapy of pruritus of atopic dermatitis?] Papaverin-Wirksam in der Therapie des Pruritus bei Dermatitis atopica?. Z. Hautkr. 65 (1990) 725-729
119. Howell R.E., Jenkins L.P., Fielding L.E., and Grimes D. Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats. Pulm. Pharmacol. 8 (1995) 83-89
120. Howell R.E., Sickels B.D., and Woeppel S.L. Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs. J. Pharmacol. Exp. Ther. 264 (1993) 609-615
121. Huang R., Cioffi J., Berg K., London R., Cidon M., Maayani S., and Mayer L. B cell differentiation factor-induced B cell maturation: Regulation via reduction in cAMP. Cell. Immunol. 162 (1995) 49-55
122. Hughes B., Howat D., Lisle H., Holbrook M., Tames T., Gozzard N., Blease K., Hughes P., Kingaby R., Warrellow G., Alexander R., Head J., Boyd E., Eaton M., Perry M., Wales M., Smith B., Owens R., Catterall C., Lumb S., Russell A., Allen R., Merriman M., Bloxham D., and Higgs G. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. Br. J. Pharmacol. 118 (1996) 1183-1191
123. Ichimura M., and Kase H. A new cyclic nucleotide phosphodiesterase isozyme expressed in the T-lymphocyte cell lines. Biochem. Biophys. Res. Commun. 193 (1993) 985-990
124. Jaffar Z.H., Sullivan P., Page C.P., and Costello J. Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics. Eur. Respir. J. 9 (1996) 456-462
125. James J.M., Kagey-Sobotka A., and Sampson H.A. Patients with severe atopic dermatitis have activated circulating basophils. J. Allergy Clin. Immunol. 91 (1993) 1155-1162
126. Jujo K., Renz H., Abe J., Gelfand E.W., and Leung D.Y. Decreased interferon gamma and increased interleukin-4 production in atopic dermatitis promotes IgE synthesis. J. Allergy Clin. Immunol. 90 (1992) 323-331
127. Jung S., Zielasek J., Kollner G., Donhauser T., Toyka K., and Hartung H.P. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 68 (1996) 1-11
128. Kammer G.M. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol. Today 9 (1988) 222-229
129. Kaneko T., Alvarez R., Ueki I.F., and Nadel J.A. Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils. Cell. Signal. 7 (1995) 527-534
130. Kawasaki A., Hoshino K., Osaki R., Mizushima Y., and Yano S. Effect of ibudilast: A novel antiasthmatic agent, on airway hypersensitivity in bronchial asthma. J. Asthma 29 (1992) 245-252
131. Kelley T.J., et al., Nakkash L., Drumm M.L. CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 13 (1995) 657-664
132. 3 HJR-(-)-rolipram binding by selective inhibitors. Biochem. J. 318 (1996) 425-436
133. Kidney J., Dominguez M., Taylor P.M., Rose M., Chung K.F., and Barnes P.J. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am. J. Respir. Crit. Care Med. 151 (1995) 1907-1914
134. Kings M.A., Chapman I., Kristersson A., Sanjar S., and Morley J. Human recombinant lymphokines and cytokines induce pulmonary eosinophilia in the guinea pig which is inhibited by ketotifen and AH 21-132. Int. Arch. Allergy Appl. Immunol. 91 (1990) 354-361
135. Kips J.C., Joos G.F., Peleman R.A., and Pauwels R.A. The effect of zardaverine, an inhibitor of phosphodiesterase isoenzymes III and IV, on endotoxin-induced airway changes in rats. Clin. Exp. Allergy 23 (1993) 518-523
136. Kita H., Abu Ghazaleh R.I., Gleich G.J., and Abraham R.T. Regulation of Ig-induced eosinophil degranulation by adenosine 3', 5'-cyclic monophosphate. J. Immunol. 146 (1991) 2712-2718
137. Kleine Tebbe J., Wicht L., Gagne H., Friese A., Schunack W., Schudt C., and Kunkel G. Inhibition of IgE-mediated histamine release from human peripheral leukocytes by selective phosphodiesterase inhibitors. Agents Actions 36 (1992) 200-206
138. Knudsen J.H., Kjaersgaard E., and Christensen N.J. Individual lymphocyte subset composition determines cAMP response to isoproterenol in mononuclear cell preparations from peripheral blood. Scand. J. Clin. Lab. Invest. 55 (1995) 9-14
139. Knudsen P.J., Dinarello C.A., and Strom T.B. Prostaglandins post-transcriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J. Immunol. 137 (1986) 3189-3194
140. Kochetkova M., Burns F.M.F., and Souness J.E. Isoprenaline induction of cAMP-phosphodiesterase in guinea-pig macrophages occurs in the presence, but not in the absence, of the phosphodiesterase type IV inhibitor rolipram. Biochem. Pharmacol. 12 (1995) 2033-2038
141. Koeter G.H., Meurs H., Kauffman H.F., and de Vries K. The role of the adrenergic system in allergy and bronchial hyperreactivity. Eur. J. Respir. Dis. [Suppl.] 121 (1982) 72-78
142. Komas N., Lugnier C., Andriantsitohaina R., and Stoclet J.C. Characterisation of cyclic nucleotide phosphodiesterases from rat mesenteric artery. Eur. J. Pharmacol. 208 (1991) 85-87
143. Komas N., Lugnier C., and Stoclet J.C. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br. J. Pharmacol. 104 (1991) 495-503
144. Kotecha S., Taylor I.K., and Shaw R.J. Pharmacological modulation of platelet-derived growth factor (B) mRNA expression in alveolar macrophages and adherent monocytes. Pulm. Pharmacol. 7 (1994) 383-391
145. Lagente V., Moodley I., Perrin S., Mottin G., and Junien J.L. Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung. Eur. J. Pharmacol. 255 (1994) 253-256
146. Lagente V., Pruniaux M.P., Junien J.L., and Moodley I. Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors. Am. J. Respir. Crit. Care Med. 151 (1995) 1720-1724
147. Lahat N., Nir E., Horenstien L., and Colin A.A. Effect of theophylline on the proportion and function of T-suppressor cells in asthmatic children. Allergy 40 (1985) 453-457
148. Lappin D., Riches D.W., Damerau B., and Whaley K. Cyclic nucleotides and their relationship to coraplement-component-C2 synthesis by human monocytes. Biochem. J. 222 (1984) 477-486
149. Lee H.J., Koyano Nakagawa N., Naito Y., Nishida J., Arai N., Arai K., and Yokota T. cAMP activates the IL-5 promoter synergistically with phorbol ester through the signaling pathway involving protein kinase A in mouse thymoma line EL-4. J. Immunol. 151 (1993) 6135-6142
150. Lenhard J.M., Kassel D.B., Rocque W.J., Hamacher L., Holmes W.D., Patel I., Hoffman C., and Luther M. Phosphorylation of a cAMP-specific phosphodiesterase (HSPDE4B2B) by mitogen-activated protein kinase. Biochem. J. 319 (1996) 751-758
151. Lewis G.M., Caccese R.G., Heaslip R.J., and Bansbach C.C. Effects of rolipram and CI-930 on IL-2 mRNA transcription in human Jurkat cells. Agents Actions 39 (1993) 89-92 Spec No, C
152. Li S.H., Chan S.C., Kramer S.M., and Hanifin J.M. Modulation of leukocyte cyclic AMP phosphodiesterase activity by recombinant interferon-gamma: Evidence for a differential effect on atopic monocytes. J. Interferon Res. 13 (1993) 197-202
153. Li S.H., Chan S.C., Toshitani A., Leung D.Y., and Hanifin J.M. Synergistic effects of interleukin 4 and interferon-gamma on monocyte phosphodiesterase activity. J. Invest. Dermatol. 99 (1992) 65-70
154. Lichtenstein L.M., and Margolis S. Histamine release in vitro: Inhibition by catecholamines and methylxanthines. Science 161 (1968) 902-903
155. Lidington E., Nohammer C., Dominguez M., Ferry B., and Rose M.L. Inhibition of the transendothelial migration of human lymphocytes but not monocytes by phosphodiesterase inhibitors. Clin. Exp. Immunol. 104 (1996) 66-71
156. Lim L.K., Hunt N.H., and Weidemann M.J. Reactive oxygen production, arachidonate metabolism and cyclic AMP in macrophages. Biochem. Biophys. Res. Commun. 114 (1983) 549-555
157. Lindgren S., Anderson K.E., Belfrage P., Degerman E., and Manganiello V.C. Relaxant effects of the selective phosphodiesterase inhibitors milrinone and OPC 3911 on isolated human mesenteric vessels. Pharmacol. Toxicol. 64 (1989) 440-445
158. Llupia J., Fernandez A.G., Berga P., and Gristwood R.W. Effects of prednisolone, salbutamol and theophylline on bronchial hyperreactivity and leucocyte chemokinesis in guinea pigs. Drugs Exp. Clin. Res. 17 (1991) 395-398
159. Logsdon P.J., Middleton Jr. E., and Coffey R.G. Stimulation of leukocyte adenyl cyclase by hydrocortisone and isoproterenol in asthmatic and nonasthmatic subjects. J. Allergy Clin. Immunol. 50 (1972) 45-56
160. Lorenz J.J., Furdon P.J., Taylor J.D., Verghese M.W., Chandra G., Kost T.A., Haneline S.A., Roner L.A., and Gray J.G. A cyclic adenosine 3',5'-monophosphate signal is required for the induction of IL-1 beta by TNF-alpha in human monocytes. J. Immunol. 155 (1995) 836-844
161. Loughney K., Martins T.J., Harris E.A., Sadhu K., Hicks J.B., Sonnenburg W.K., Beavo J.A., and Ferguson K. Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases. J. Biol. Chem. 271 (1996) 796-806
162. Louis R., Bury T., Corhay J.L., and Radermecker M. LY 186655, a phosphodiesterase inhibitor, inhibits histamine release from human basophils, lung and skin fragments. Int. J. Immunopharmacol. 14 (1992) 191-194
163. Louis R.E., and Radermecker M.F. Substance P-induced histamine release from human basophils, skin and lung fragments: Effect of nedocromil sodium and theophylline. Int. Arch. Allergy Appl. Immunol. 92 (1990) 329-333
164. Lugnier C., and Schini V.B. Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells. Biochem. Pharmacol. 39 (1990) 75-84
165. Lugnier C., Schoeffter P., Le Bec A., Strouthou E., and Stoclet J.C. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol. 35 (1986) 1743-1751
166. Manganiello V.C., Taira M., Degerman E., and Belfrage P. Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). Cell. Signal. 7 (1995) 445-455
167. Manning C.D., McLaughlin M.M., Livi G.P., Cieslinski L.B., Torphy T.J., and Barnette M.S. Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B. J. Pharmacol. Exp. Ther. 276 (1996) 810-818
168. Manzini S., Perretti F., Abelli L., Evangelista S., Seeds E.A., and Page C.P. Isbufylline, a new xanthine derivative, inhibits airway hyperresponsiveness and airway inflammation in guinea pigs. Eur. J. Pharmacol. 249 (1993) 251-257
169. Mapp C., Boschetto P., dal Vecchio L., Crescioli S., de Marzo N., Paleari D., and Fabbri L.M. Protective effect of antiasthma drugs on late asthmatic reactions and increased airway responsiveness induced by toluene diisocyanate in sensitized subjects. Am. Rev. Respir. Dis. 136 (1987) 1403-1407
170. Marcoz P., Prigent A.F., Lagarde M., and Nemoz G. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents. Mol. Pharmacol. 44 (1993) 1027-1035
171. Martins T.J., Mumby M.C., and Beavo J.A. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J. Biol. Chem. 257 (1982) 1973-1979
172. Marukawa S., Hatake K., Wakabayashi I., and Hishida S. Vasorelaxant effects of oxpentifylline and theophylline on rat isolated aorta. J. Pharm. Pharmacol. 46 (1994) 342-345
173. Mary D., Aussel C., Ferrua B., and Fehlmann M. Regulation of interleukin 2 synthesis by cAMP in human T cells. J. Immunol. 139 (1987) 1179-1184
174. McAllister Lucas L.M., Haik T.L., Colbran J.L., Sonnenburg W.K., Seger D., Turko I.V., Beavo J.A., Francis S.H., and Corbin J.D. An essential aspartic acid at each of two allosteric cGMP-binding sites of a cGMP-specific phosphodiesterase. J. Biol. Chem. 270 (1995) 30671-30679
175. Meacci E., Taira M., Moos Jr. M., Smith C.J., Movsesian M.A., Degerman E., Belfrage P., and Manganiello V. Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. Proc. Natl. Acad. Sci. USA 89 (1992) 3721-3725
176. Mentz F., Merle Beral H., Ouaaz F., and Binet J.L. Theophylline, a new inducer of apoptosis in B-CLL: Role of cyclic nucleotides. Br. J. Haematol. 90 (1995) 957-959
177. Meurs H., Kauffman H.F., Koeter G.H., Timmermans A., and de Vries K. Regulation of the beta-receptor-adenylate cyclase system in lymphocytes of allergic patients with asthma: Possible role for protein kinase C in allergen-induced nonspecific refractoriness of adenylate cyclase. J. Allergy Clin. Immunol. 80 (1987) 326-339
178. Meurs H., Kauffman H.F., Timmermans A., De Monchy J.G., Koeter G.H., and de Vries K. Specific immunological modulation of lymphocyte adenylate cyclase in asthmatic patients after allergenic bronchial provocation. Int. Arch. Allergy Appl. Immunol. 81 (1986) 224-229
179. Meurs H., Koeter G.H., de Vries K., and Kauffman H.F. The beta-adrenergic system and allergic bronchial asthma: Changes in lymphocyte beta-adrenergic receptor number and adenylate cyclase activity after an allergen-induced asthmatic attack. J. Allergy Clin. Immunol. 70 (1982) 272-280
180. Michaeli T., Bloom T.J., Martins T., Loughney K., Ferguson K., Riggs M., Rodgers L., Beavo J.A., and Wigler M. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J. Biol. Chem. 268 (1993) 12925-12932
181. Michie A.M., Lobban M., Muller T., Harnett M.M., and Houslay M.D. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: Analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. Cell. Signal. 8 (1996) 97-110
182. Miyahara M., Ito M., Itoh H., Shiraishi T., Isaka N., Konishi T., and Nakano T. Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: Characterization and the effects of E4021. Eur. J. Pharmacol. 284 (1995) 25-33
183. Miyamoto K., Kurita M., Sakai R., Sanae F., Wakusawa S., and Takagi K. Cyclic nucleotide phosphodiesterase isoenzymes in guinea-pig tracheal muscle and bronchorelaxation by alkylxanthines. Biochem. Pharmacol. 48 (1994) 1219-1223
184. Molnar Kimber K., Yonno L., Heaslip R., and Weichman B. Modulation of TNF alpha and IL-1 beta from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions 39 (1993) 77-79 Spec No, C
185. Moodley I., Sotsios Y., and Bertin B. Modulation of oxazolone-induced hypersensitivity in mice by selective PDE inhibitors. Mediators Inflamm. 4 (1995) 112-116
186. Motojima S., Fukuda T., and Makino S. Measurement of beta-adrenergic receptors on lymphocytes in normal subjects and asthmatics in relation to beta-adrenergic hyperglycaemic response and bronchial responsiveness. Allergy 38 (1983) 331-337
187. Mukai J., Asai T., Naka M., and Tanaka T. Separation and characterization of a novel isoenzyme of cyclic nucleotide phosphodiesterase from rat cerebrum. Br. J. Pharmacol. 111 (1994) 389-390
188. Muller T., Engels P., and Fozard J.R. Subtypes of the type 4 cAMP phosphodiesterases: Structure, regulation and selective inhibition. Trends Pharmacol. Sci. 17 (1996) 294-298
189. Munoz E., Zubiaga A.M., Merrow M., Sauter N.P., and Huber B.T. Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-mediated activation: Role of cAMP in T cell proliferation. J. Exp. Med. 172 (1990) 95-103
190. Musial J., Milewski M., Undas A., Kopinski P., Duplaga M., and Szczeklik A. Interferon-gamma in the treatment of atopic dermatitis: Influence on T-cell activation. Allergy 50 (1995) 520-523
191. Naclerio R.M., Bartenfelder D., Proud D., Togias A.G., Meyers D.A., Kagey Sobotka A., Norman P.S., and Lichtenstein L.M. Theophylline reduces histamine release during pollen-induced rhinitis. J. Allergy Clin. Immunol. 78 (1986) 874-876
192. Nagai H., Takeda H., Iwama T., Yamaguchi S., and Mori H. Studies on antiallergic action of AH 21-132, a novel isozyme-selective phosphodiesterase inhibitor in airways. Jpn. J. Pharmacol. 67 (1995) 149-156
193. Nakagawa K., Miller F.N., Knott A.W., and Edwards M.J. Pentoxifylline inhibits FMLP-induced macromolecular leakage. Am. J. Physiol. 269 (1995) H239-H245
194. Newsholme S.J., and Schwartz L. cAMP-specific phosphodiesterase inhibitor, rolipram, reduces eosinophil infiltration evoked by leukotrienes or by histamine in guinea pig conjunctiva. Inflammation 17 (1993) 25-31
195. Nicholson C.D., and Shahid M. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes-their potential utility in the therapy of asthma. Pulm. Pharmacol. 7 (1994) 1-17
196. Nicholson C.D., Shahid M., Bruin J., Barron E., Spiers I., de Boer J., van Amsterdam R.G., Zaagsma J., Kelly J.J., Dent G., et al. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma. J. Pharmacol. Exp. Ther. 274 (1995) 678-687
197. Nielson C.P., Crowley J.J., Cusack B.J., and Vestal R.E. Therapeutic concentrations of theophylline and enprofylline potentiate catecholamine effects and inhibit leukocyte activation. J. Allergy Clin. Immunol. 78 (1986) 660-667
198. Nielson C.P., Vestal R.E., Sturm R.J., and Heaslip R. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J. Allergy Clin. Immunol. 86 (1990) 801-808
199. Nishioka K., Matsunaga T., and Katayama I. Gamma-interferon therapy for severe cases of atopic dermatitis of the adult type. J. Dermatol. 22 (1995) 181-185
200. Noel P.E., Fletcher J.R., and Thompson W.J. Rolipram and isoproterenol reverse platelet activating factor-induced increases in pulmonary microvascular permeability and vascular resistance. J. Surg. Res. 59 (1995) 159-164
201. Nourshargh S., and Hoult J.R. Inhibition of human neutrophil degranulation by forskolin in the presence of phosphodiesterase inhibitors. Eur. J. Pharmacol. 122 (1986) 205-212
202. Novak T.J., and Rothenberg E.V. cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells. Proc. Natl. Acad. Sci. USA 87 (1990) 9353-9357
203. O' Connell J.C., McCallum J.F., McPhee I., Wakefield J., Houslay E.S., Wishart W., Bolger G., Frame M., and Houslay M.D. The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5). Biochem. J. 318 (1996) 255-262
204. Obernolte R., Bhakta S., Alvarez R., Bach C., Zuppan P., Mulkins M., Jarnagin K., and Shelton E.R. The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family. Gene 129 (1993) 239-247
205. Odelram H., Bjorksten B., Chan S.C., Hanifin J.M., and Kjellman N.I. Neonatal leukocyte cAMP-phosphodiesterase determination is not suitable for allergy prediction. Allergy 49 (1994) 677-679
206. Ohmen J.D., Hanifin J.M., Nickoloff B.J., Rea T.H., Wyzykowski R., Kim J., Jullien D., McHugh T., Nassif A.S., Chan S.C., et al. Overexpression of IL-10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity reactions. J. Immunol. 154 (1995) 1956-1963
207. Orange R.P., Kaliner M.A., Laraia P.J., and Austen K.F. Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. II. Influence of cellular levels of cyclic AMP. Fed. Proc. 30 (1971) 1725-1729
208. Ortiz J.L., Cortijo J., Valles J.M., Bou J., and Morcillo E.J. Rolipram inhibits airway microvascular leakage induced by platelet-activating factor, histamine and bradykinin in guinea-pigs. J. Pharm. Pharmacol. 45 (1993) 1090-1092
209. Ortiz J.L., Cortijo J., Valles J.M., and Morcillo E.J. Rolipram inhibits PAF-induced airway microvascular leakage in guinea-pig: A comparison with milrinone and theophylline. Fundam. Clin. Pharmacol. 6 (1992) 247-249
210. Ortiz J.L., Valles J.M., MartiCabrera M., Cortijo J., and Morcillo E.J. Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs. Naunyn Schmiedeberg's Arch. Pharmacol. 353 (1996) 200-206
211. Ostlere L.S., Mallett R.B., Kaminski A., Kaminski E.R., Pereira R.S., and Holden C.A. gamma-Interferon production in atopic dermatitis shows differential modification by phosphodiesterase and prostaglandin inhibition. Br. J. Dermatol. 133 (1995) 1-5
212. Pan X., Arauz E., Krzanowski J.J., Fitzpatrick D.F., and Poison J.B. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem. Pharmacol. 48 (1994) 827-835
213. Parker C.W., Kennedy S., and Eisen A.Z. Leukocyte and lymphocyte cyclic AMP responses in atopic eczema. J. Invest. Dermatol. 68 (1977) 302-306
214. Parker C.W., and Smith J.W. Alterations in cyclic adenosine monophosphate metabolism in human bronchial asthma. I. Leukocyte responsiveness to beta-adrenergic agents. J. Clin. Invest. 52 (1973) 48-59
215. Paul Eugene N., Kolb J.P., Calenda A., Gordon J., Kikutani H., Kishimoto T., Mencia Huerta J.M., Braquet P., and Dugas B. Functional interaction between beta 2-adrenoceptor agonists and interleukin-4 in the regulation of CD23 expression and release and IgE production in human. Mol. Immunol. 30 (1993) 157-164
216. Paul Eugene N., Kolb J.P., Damais C., Abadie A., Mencia Huerta J.M., Braquet P., Bousquet J., and Dugas B. Beta 2-adrenoceptor agonists regulate the IL-4-induced phenotypical changes and IgE-dependent functions in normal human monocytes. J. Leukoc. Biol. 55 (1994) 313-320
217. Pauwels R., van Renterghem D., van der Straeten M., Johannesson N., and Persson C.G. The effect of theophylline and enprofylline on allergen-induced bronchoconstriction. J. Allergy Clin. Immunol. 76 (1985) 583-590
218. Peachell P.T., MacGlashan Jr. D.W., Lichtenstein L.M., and Schleimer R.P. Regulation of human basophil and lung mast cell function by cyclic adenosine monophosphate. J. Immunol. 140 (1988) 571-579
219. Peachell P.T., Undem B.J., Schleimer R.P., MacGlashan Jr. D.W., Lichtenstein L.M., Cieslinski L.B., and Torphy T.J. Preliminary identification and role of phosphodiesterase isozymes in human basophils. J. Immunol. 148 (1992) 2503-2510
220. Pearce F.L., Befus A.D., Gauldie J., and Bienenstock J. Mucosal mast cells. II. Effects of anti-allergic compounds on histamine secretion by isolated intestinal mast cells. J. Immunol. 128 (1982) 2481-2486
221. Pene J., Rousset F., Briere F., Chretien I., Bonnefoy J.Y., Spits H., Yokota T., Arai N., Arai K., Banchereau J., et al. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc. Natl. Acad. Sci. USA 85 (1988) 6880-6884
222. Persson C.G., Erjefalt I., and Andersson P. Leakage of macromolecules from guineapig tracheobronchial microcirculation. Effects of allergen, leukotrienes, tachykinins, and anti-asthma drugs. Acta Physiol. Scand. 127 (1986) 95-105
223. Piriev N.I., Khramtsov N.V., and Lipkin V.M. Cloning and characterization of the gene encoding the cGMP-phosphodiesterase gamma-subunit of human rod photoreceptor cells. Gene 151 (1994) 297-301
224. Pittler S.J., Baehr W., Wasmuth J.J., McConnell D.G., Champagne M.S., van Tuinen P., Ledbetter D., and Davis R.L. Molecular characterization of human and bovine rod photoreceptor cGMP phosphodiesterase alpha-subunit and chromosomal localization of the human gene. Genomics 6 (1990) 272-283
225. Platzer C., Meisel C., Vogt K., Platzer M., and Volk H.D. Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int. Immunol. 7 (1995) 517-523
226. Pober J.S., Slowik M.R., De Luca L.G., and Ritchie A.J. Elevated cyclic AMP inhibits endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1. J. Immunol. 150 (1993) 5114-5123
227. Prabhakar U., Lipshutz D., Bartus J.O., Slivjak M.J., Smith E.F., Lee J.C., and Esser K.M. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDEIV) inhibitor. Int. J. Immunopharmacol. 16 (1994) 805-816
228. Qian Y., Girard V., Martin C.A., Molimard M., and Advenier C. Rolipram, but not siguazodan or zaprinast, inhibits the excitatory noncholinergic neurotransmission in guinea-pig bronchi. Eur. Respir. J. 7 (1994) 306-310
229. Qian Y., Naline E., Karlsson J.A., Raeburn D., and Advenier C. Effects of rolipram and siguazodan on the human isolated bronchus and their interaction with isoprenaline and sodium nitroprusside. Br. J. Pharmacol. 109 (1993) 774-778
230. Rabe K.F., Magnussen H., and Dent G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur. Respir. J. 8 (1995) 637-642
231. Rabe K.F., Tenor H., Dent G., Schudt C., Liebig S., and Magnussen H. Phosphodiesterase isozymes modulating inherent tone in human airways: Identification and characterization. Am. J. Physiol. 264 (1993) L464-L536
232. Rabe K.F., Tenor H., Dent G., Schudt C., Nakashima M., and Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am. J. Physiol. 266 (1994) 1147-1152
233. Raeburn D., and Karlsson J.A. Effects of isoenzyme-selective inhibitors of cyclic nucleotide phosphodiesterase on microvascular leak in guinea pig airways in vivo. J. Pharmacol. Exp. Ther. 267 (1993) 1147-1152
234. Raeburn D., Souness J.E., Tomkinson A., and Karlsson J.A. Isozyme-selective cyclic nucleotide phosphodiesterase inhibitors: Biochemistry, pharmacology and therapeutic potential in asthma. Prog. Drug Res. 40 (1993) 9-32
235. Raeburn D., Underwood S.L., Lewis S.A., Woodman V.R., Battram C.H., Tomkinson A., Sharma S., Jordan R., Souness J.E., Webber S.E., et al. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br. J. Pharmacol. 113 (1994) 1423-1431
236. Raeburn D., and Woodman V.R. Effect of theophylline administered intratracheally as a dry powder formulation on bronchospasm and airway microvascular leakage in the anaesthetized guinea-pig. Pulm. Pharmacol. 7 (1994) 243-249
237. Reinhardt R.R., Chin E., Zhou J., Taira M., Murata T., Manganiello V.C., and Bondy C.A. Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J. Clin. Invest. 95 (1995) 1528-1538
238. Reinhold U., Wehrmann W., Kukel S., and Kreysel H.W. Evidence that defective interferon-gamma production in atopic dermatitis patients is due to intrinsic abnormalities. Clin. Exp. Immunol. 79 (1990) 374-379
239. Reinhold U., Wehrmann W., Kukel S., and Kreysel H.W. Recombinant interferon-gamma in severe atopic dermatitis [letter]. Lancet 335 (1990) 1282
240. Renz H., Jujo K., Bradley K.L., Domenico J., Gelfand E.W., and Leung D.Y. Enhanced IL-4 production and IL-4 receptor expression in atopic dermatitis and their modulation by interferon-gamma. J. Invest. Dermatol. 99 (1992) 403-408
241. Rieckmann P., Weber F., Gunther A., Martin S., Bitsch A., Broocks A., Kitze B., Weber T., Borner T., and Poser S. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J. Neuroimmunol. 64 (1996) 193-200
242. Rivkin I., and Neutze J.A. Influence of cyclic nucleotides and a phosphodiesterase inhibitor on in vitro human blood neutrophil chemotaxis. Arch. Int. Pharmacodyn. Ther. 228 (1977) 196-204
243. Robichon A. A new cGMP phosphodiesterase isolated from bovine platelets is substrate for cAMP- and cGMP-dependent protein kinases: Evidence for a key role in the process of platelet activation. J. Cell. Biochem. 47 (1991) 147-157
244. Robicsek S.A., Blanchard D.K., Djeu J.Y., Krzanowski J.J., Szentivanyi A., and Polson J.B. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem. Pharmacol. 42 (1991) 869-877
245. Roper R.L., Brown D.M., and Phipps R.P. Prostaglandin E2 promotes B lymphocyte Ig isotype switching to IgE. J. Immunol. 154 (1995) 162-170
246. Roper R.L., Conrad D.H., Brown D.M., Warner G.L., and Phipps R.P. Prostaglandin E2 promotes IL-4 induced IgE and IgGl synthesis. J. Immunol. 145 (1990) 2644-2651
247. Rossi P., Giorgi M., Geremia R., and Kincaid R.L. Testis-specific calmodulin-dependent phosphodiesterase. A distinct high affinity cAMP isoenzyme immunologically related to brain calmodulin-dependent cGMP phosphodiesterase. J. Biol. Chem. 263 (1988) 15521-15527
248. Rott O., Cash E., and Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur. J. Immunol. 23 (1993) 1745-1751
249. Rousseau E., Gagnon J., and Lugnier C. Biochemical and pharmacological characterization of cyclic nucleotide phosphodiesterase in airway epithelium. Mol. Cell. Biochem. 140 (1994) 171-175
250. Safko M.J., Chan S.C., Cooper K.D., and Hanifin J.M. Heterologous desensitization of leukocytes: A possible mechanism of beta adrenergic blockade in atopic dermatitis. J. Allergy Clin. Immunol. 68 (1981) 218-225
251. Sagara H., Fuiuda T., Okada T., Ishikawa A., and Makino S. Theophylline at therapeutic concentration suppresses PAF-induced upregulation of Mac-1 on human eosinophils. Clin. Exp. Allergy [Suppl.] 26 (1996) 16-21
252. Sanjar S., Aoki S., Boubekeur K., Chapman I.D., Smith D., Kings M.A., and Morley J. Eosinophil accumulation in pulmonary airways of guinea-pigs induced by exposure to an aerosol of platelet-activating factor: Effect of anti-asthma drugs. Br. J. Pharmacol. 99 (1990) 267-272
253. Sanjar S., Aoki S., Kristersson A., Smith D., and Morley J. Antigen challenge induces pulmonary airway eosinophil accumulation and airway hyperreactivity in sensitized guinea-pigs: The effect of anti-asthma drugs. Br. J. Pharmacol. 99 (1990) 679-686
254. Santing R.E., Olymulder C.G., van der Molen K., Meurs H., and Zaagsma J. Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs. Eur. J. Pharmacol. 275 (1995) 75-82
255. Sato K., Stelzner T.J., O'Brien R.F., Weil J.V., and Welsh C.H. Pentoxifylline lessens the endotoxin-induced increase in albumin clearance across pulmonary artery endothelial monolayers with and without neutrophils. Am. J. Respir. Cell Mol. Biol. 4 (1991) 219-227
256. Sawai T., Ikai K., and Uehara M. Elevated cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from children with atopic dermatitis. Br. J. Dermatol. 132 (1995) 22-24
257. Schade F.U., and Schudt C. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur. J. Pharmacol. 230 (1993) 9-14
258. Scherer L.J., Diamond R.A., and Rothenberg E.V. Developmental regulation of cAMP signaling pathways in thymocyte development. Thymus 23 (1994) 231-257
259. Schmidt J., Hatzelmann A., Fleissner S., Heimann Weitschat I., Lindstaedt R., and Szelenyi I. Effect of phosphodiesterase inhibition on IL-4 and IL-5 production of the murine TH2-type T cell clone D10.G4. 1. Immunopharmacology 30 (1995) 191-198
260. Schneider H.H., Schmiechen R., Brezinski M., and Seidler J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. J. Pharmacol. 127 (1986) 105-115
261. Schudt C., Tenor H., and Hatzelmann A. PDE isoenzymes as targets for anti-asthma drugs. Eur. Respir. J. 8 (1995) 1179-1183
262. Schudt C., Winder S., Eltze M., Kilian U., and Beume R. Zardaverine: A cyclic AMP specific PDE III/IV inhibitor. Agents Actions [Suppl.] 34 (1991) 379-402
263. Schudt C., Winder S., Forderkunz S., Hatzelmann A., and Ullrich V. Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai. Naunyn Schmiedeberg's Arch. Pharmacol. 344 (1991) 682-690
264. Scordamaglia A., Ciprandi G., Ruffoni S., Caria M., Paolieri F., Venuti D., and Canonica G.W. Theophylline and the immune response: In vitro and in vivo effects. Clin. Immunol. Immunopathol. 48 (1988) 238-246
265. Seeger W., Hansen T., Rossig R., Schmehl T., Schutte H., Kramer H.J., Walmrath D., Weissmann N., Grimminger F., and Suttorp N. Hydrogen peroxide-induced increase in lung endothelial and epithelial permeability-effect of adenylate cyclase stimulation and phosphodiesterase inhibition. Microvasc. Res. 50 (1995) 1-17
266. Seldon P.M., Barnes P.J., Meja K., and Giembycz M.A. Suppression of lipopolysac-charide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: Interaction with stimulants of adenylyl cyclase. Mol. Pharmacol. 48 (1995) 747-757
267. Sette C., and Conti M. Phosphorylation and activation of cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. J. Biol. Chem. 271 (1996) 16526-16534
268. Sette C., Iona S., and Conti M. The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J. Biol. Chem. 269 (1994) 9245-9252
269. Sette C., Vicini E., and Conti M. The rat PDE3/IVd phosphodiesterase gene codes for muliple proteins differentially activated by cAMP-dependent protein kinase. J. Biol. Chem. 269 (1994) 18271-18274
270. Shahid M., van Amsterdam R.G., de Boer J., ten Berge R.E., Nicholson C.D., and Zaagsma J. The presence of five cyclic nucleotide phosphodiesterase isoenzyme activities in bovine tracheal smooth muscle and the functional effects of selective inhibitors. Br. J. Pharmacol. 104 (1991) 471-477
271. Sharma R.K. Phosphorylation and characterization of bovine heart calmodulin-dependent phosphodiesterase. Biochemistry 30 (1991) 5963-5968
272. Sharma R.K., Adachi A.M., Adachi K., and Wang J.H. Demonstration of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by monoclonal antibodies. J. Biol. Chem. 259 (1984) 9248-9254
273. Sharma R.K., and Kalra J. Characterization of calmodulin-dependent cyclic nucleotide phosphodiesterase isoenzymes. Biochem. J. 299 (1994) 97-100
274. Sharma R.K., and Wang J.H. Purification and characterization of bovine lung calmodulin-dependent cyclic nucleotide phosphodiesterase. An enzyme containing calmodulin as a subunit. J. Biol. Chem. 261 (1986) 14160-14166
275. Shenolikar S., Thompson W.J., and Strada S.J. Characterization of a Ca2+-calmodulin-stimulated cyclic GMP phosphodiesterase from bovine brain. Biochemistry 24 (1985) 672-678
276. Shohat B., Volovitz B., and Varsano I. Induction of suppressor T cells in asthmatic children by theophylline treatment. Clin. Allergy 13 (1983) 487-493
277. Shore A., Dosch H., and Gelfand E.W. Induction and separation of antigen-dependent T helper and T suppressor cells in man. Nature 274 (1978) 586-587
278. Shupack J., Stiller M., Meola Jr. T., and Orbuch P. Papaverine hydrochloride in the treatment of atopic dermatitis: A double-blind, placebo-controlled crossover clinical trial to reassess safety and efficacy. Dermatologica 183 (1991) 21-24
279. Silver P.J., Hamel L.T., Perrone M.H., Bentley R.G., Bushover C.R., and Evans D.B. Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur. J. Pharmacol. 150 (1988) 85-94
280. Simon M.R., Cooper K.D., Norris R.B., Blok B., and King C.L. Antigen presenting cell-independent cytokine and spontaneous in vitro IgE production in patients with atopic dermatitis: Increased interferon-gamma production and lack of effects of in vivo low-dose interferon-gamma treatment. J. Allergy Clin. Immunol. 96 (1995) 84-91
281. Sinha B., Semmler J., Eisenhut T., Eigler A., and Endres S. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur. J. Immunol. 25 (1995) 147-153
282. Snijdewint F.G., Kalinski P., Wierenga E.A., Bos J.D., and Kapsenberg M.L. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J. Immunol. 150 (1993) 5321-5329
283. Sommer N., Loschmann P.A., Northoff G.H., Weller M., Steinbrecher A., Steinbach J.P., Lichtenfels R., Meyermann R., Riethmuller A., Fontana A., et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1 (1995) 244-248
284. Sonnenburg W.K., Mullaney P.J., and Beavo J.A. Molecular cloning of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase cDNA. Identification and distribution of isozyme variants. J. Biol. Chem. 266 (1991) 17655-17661
285. Souness J.E., Diocee B.K., Martin W., and Moodie S.A. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells. Biochem. J. 266 (1990) 127-132
286. Souness J.E., Griffin M., Maslen C., Ebsworth K., Scott L.C., Pollock K., Palfreyman M.N., and Karlsson J.A. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFa generation from human monocytes by interacting with a "low-affinity" phosphodiesterase 4 conformer. Br. J. Pharmacol. 118 (1996) 649-658
287. Souness J.E., Maslen C., Webber S., Foster M., Raeburn D., Palfreyman M.N., Ashton M.J., and Karlsson J.A. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: Comparison with rolipram. Br. J. Pharmacol. 115 (1995) 39-46
288. Souness J.E., and Scott L.C. Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase. Biochem. J. 291 (1993) 389-395
289. Souness J.E., Villamil M.E., Scott L.C., Tomkinson A., Giembycz M.A., and Raeburn D. Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone. Br. J. Pharmacol. 111 (1994) 1081-1088
290. Soyombo A.A., Angelini G.D., and Newby A.C. Neointima formation is promoted by surgical preparation and inhibited by cyclic nucleotides in human saphenous vein organ cultures. J. Thorac. Cardiovasc. Surg. 109 (1995) 2-12
291. Spatafora M., Chiappara G., Merendino A.M., D'Amico D., Bellia V., and Bonsignore G. Theophylline suppresses the release of tumour necrosis factor-alpha by blood monocytes and alveolar macrophages. Eur. Respir. J. 7 (1994) 223-228
292. Spina D., Harrison S., and Page C.P. Regulation by phosphodiesterase isoenzymes of non-adrenergic non-cholinergic contraction in guinea-pig isolated main bronchus. Br. J. Pharmacol. 116 (1995) 2334-2340
293. Stawiski M.A., Rusin L.J., Burns T.L., Weinstein G.D., and Voorhees J.J. Ro 20-1724: An agent that significantly improves psoriatic lesions in double-blind clinical trials. J. Invest. Dermatol. 73 (1979) 261-263
294. Stelzner T.J., Weil J.V., and O'Brien R.F. Role of cyclic adenosine monophosphate in the induction of endothelial barrier properties. J. Cell. Physiol. 139 (1989) 157-166
295. Sullivan P., Bekir S., Jaffar Z., Page C., Jeffery P., and Costello J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 343 (1994) 1006-1008
296. Sung S.S., and Walters J.A. Increased cyclic AMP levels enhance IL-1 alpha and IL-1 beta mRNA expression and protein production in human myelomonocytic cell lines and monocytes. J. Clin. Invest. 88 (1991) 1915-1923
297. Suttorp N., Weber U., Welsch T., and Schudt C. Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J. Clin. Invest. 91 (1993) 1421-1428
298. Svensjo E., Andersson K.E., Bouskela E., Cyrino F.Z., and Lindgren S. Effects of two vasodilatory phosphodiesterase inhibitors on bradykinin-induced permeability increase in the hamster cheek pouch. Agents Actions 39 (1993) 35-41
299. Swinnen J.V., Joseph D.R., and Conti M. The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP. Proc. Natl. Acad. Sci. USA 86 (1989) 8197-8201
300. Swinnen J.V., Tsikalas K.E., and Conti M. Properties and hormonal regulation of two structurally related cAMP phosphodiesterases from the rat Sertoli cell. J. Biol. Chem. 266 (1991) 18370-18377
301. Szentivanyi A., Heim O., and Schultze P. Changes in adrenoceptor densities in membranes of lung tissue and lymphocytes from patients with atopic disease. Ann. NY Acad. Sci. 332 (1979) 295-298
302. Takahashi S., Oida K., Fujiwara R., Maeda H., Hayashi S., Takai H., Tamai T., Nakai T., and Miyabo S. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J. Cardiovasc. Pharmacol. 20 (1992) 900-906
303. Tarayre J.P., Aliaga M., Barbara M., Malfetes N., Vieu S., and Tisne Versailles J. Theophylline reduces pulmonary eosinophilia after various types of active anaphylactic shock in guinea-pigs. J. Pharm. Pharmacol. 43 (1991) 877-879
304. Tashkin D.P., Conolly M.E., Deutsch R.I., Hui K.K., Littner M., Scarpace P., and Abrass I. Subsensitization of beta-adrenoceptors in airways and lymphocytes of healthy and asthmatic subjects. Am. Rev. Respir. Dis. 125 (1982) 185-193
305. Teixeira M.M., Rossi A.G., Williams T.J., and Hellewell P.G. Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig. Br. J. Pharmacol. 112 (1994) 332-340
306. Tenor H., Hatzelmann A., Church M.K., Schudt C., and Shute J.K. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br. J. Pharmacol. 118 (1996) 1727-1735
307. Tenor H., Hatzelmann A., Kupferschmidt R., Stanciu L., Djukanovic R., Schudt C., Wendel A., Church M.K., and Shute J.K. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin. Exp. Allergy 25 (1995) 625-633
308. Tenor H., Staniciu L., Schudt C., Hatzelmann A., Wendel A., Djukanovic R., Church M.K., and Shute J.K. Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes. Clin. Exp. Allergy 25 (1995) 616-624
309. H1 response in situ: An immunohistochemical study. J. Allergy Clin. Immunol. 97 (1996) 828-837
310. Tokuyama K., Yokoyama T., Arakawa H., Morikawa A., and Kuroume T. Effects of cilostazol, a cyclic nucleotide phosphodiesterase III inhibitor, on substance P-induced airflow obstruction and airway microvascular leakage in guinea pigs. Pharmacology 48 (1994) 301-307
311. Tomkinson A., Karlsson J.A., and Raeburn D. Comparison of the effects of selective inhibitors of phosphodiesterase types III and IV in airway smooth muscle with differing beta-adrenoceptor subtypes. Br. J. Pharmacol. 108 (1993) 57-61
312. Tomlinson P.R., Wilson J.W., and Stewart A.G. Salbutamol inhibits the proliferation of human airway smooth muscle cells grown in culture: Relationship to elevated cAMP levels. Biochem. Pharmacol. 49 (1995) 1809-1819
313. Torphy T.J., Barnette M.S., Hay D.W., and Underwood D.C. Phosphodiesterase FV inhibitors as therapy for eosinophil-induced lung injury in asthma. Environ. Health Perspect. 102 Suppl. 10 (1994) 79-84
314. Torphy T.J., Burman M., Huang L.B., and Tucker S.S. Inhibition of the low km cyclic AMP phosphodiesterase in intact canine trachealis by SK& F 94836: Mechanical and biochemical responses. J. Pharmacol. Exp. Ther. 246 (1988) 843-850
315. Torphy T.J., and Cieslinski L.B. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle. Mol. Pharmacol. 37 (1990) 206-214
316. Torphy T.J., Stadel J.M., Burman M., Cieslinski L.B., McLaughlin M.M., White J.R., and Livi G.P. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J. Biol. Chem. 267 (1992) 1798-1804
317. Torphy T.J., and Undem B.J. Phosphodiesterase inhibitors: New opportunities for the treatment of asthma. Thorax 46 (1991) 512-523
318. Torphy T.J., Undem B.J., Cieslinski L.B., Luttmann M.A., Reeves M.L., and Hay D.W. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J. Pharmacol. Exp. Ther. 265 (1993) 1213-1223
319. Torphy T.J., Zhou H.L., Burman M., and Huang L.B. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis. Mol. Pharmacol. 39 (1991) 376-384
320. Torphy T.J., Zhou H.L., and Cieslinski L.B. Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. J. Pharmacol. Exp. Ther. 263 (1992) 1195-1205
321. Torphy T.J., Zhou H.L., Foley J.J., Sarau H.M., Manning C.D., and Barnette M.S. Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of beta-adrenoceptor agonists. J. Biol. Chem. 270 (1995) 23598-23604
322. Turner C.R., Andresen C.J., Smith W.B., and Watson J.W. Effects of rolipram on responses to acute and chronic antigen exposure in monkeys. Am. J. Respir. Crit. Care Med. 149 (1994) 1153-1159
323. Turner C.R., Cohan V.L., Cheng J.B., Showell H.J., Pazoles C.J., and Watson J.W. The in vivo pharmacology of CP-80,633, a selective inhibitor of phosphodiesterase 4. J. Pharmacol. Exp. Ther. 278 (1996) 1349-1355
324. Turner N.C., Wood L.J., Burns F.M., Gueremy T., and Souness J.E. The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages. Br. J. Pharmacol. 108 (1993) 876-883
325. Undem B.J., Meeker S.N., and Chen J. Inhibition of neurally mediated nonadrenergic, noncholinergic contractions of guinea pig bronchus by isozyme-selective phosphodiesterase inhibitors. J. Pharmacol. Exp. Ther. 271 (1994) 811-817
326. Underwood D.C., Kotzer C.J., Bochnowicz S., Osborn R.R., Luttmann M.A., Hay D.W., and Torphy T.J. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J. Pharmacol. Exp. Ther. 270 (1994) 250-259
327. Underwood D.C., Osborn R.R., Novak L.B., Matthews J.K., Newsholme S.J., Undem B.J., Hand J.M., and Torphy T.J. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J. Pharmacol. Exp. Ther. 266 (1993) 306-313
328. van der Pouw Kraan T.C., Boeije L.C., Smeenk R.J., Wijdenes J., and Aarden L.A. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med. 181 (1995) 775-779
329. van der Pouw Kraan T., van Kooten C., Rensink I., and Aarden L. Interleukin (IL)-4 production by human T cells: Differential regulation of IL-4 vs. IL-2 production. Eur. J. Immunol. 22 (1992) 1237-1241
330. Verghese M.W., McConnell R.T., Lenhard J.M., Hamacher L., and Jin S.L. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol. Pharmacol. 47 (1995) 1164-1171
331. Verghese M.W., McConnell R.T., Strickland A.B., Gooding R.C., Stimpson S.A., Yarnall D.P., Taylor J.D., and Furdon P.J. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J. Pharmacol. Exp. Ther. 272 (1995) 1313-1320
332. Viczian A.S., Piriev N.I., and Farber D.B. Isolation and characterization of a cDNA encoding the alpha' subunit of human cone cGMP-phosphodiesterase. Gene 166 (1995) 205-211
333. Viherluoto J., Palkama T., Silvennoinen O., and Hurme M. Cyclic adenosine monophosphate decreases the secretion, but not the cell-associated levels, of interleukin-1 beta in lipopolysaccharide-activated human monocytes. Scand. J. Immunol. 34 (1991) 121-125
334. Virtanen T., Maggi E., Manetti R., Piccinni M.P., Sampognaro S., Parronchi P., De Carli M., Zuccati G., and Romognani S. No relationship between skin-infiltrating TH2-like cells and allergen-specific IgE response in atopic dermatitis. J. Allergy Clin. Immunol. 96 (1995) 411-420
335. Wagner U., Bredenbroker D., Fehmann H., Schwarz F., Schudt C., and Von Wichert P. Effects of selective and non-selective phosphodiesterase inhibitors on tracheal mucus secretion in the rat. Eur. J. Pharmacol. 298 (1996) 265-270
336. Ward A.J., McKenniff M., Evans J.M., Page C.P., and Costello J.F. Theophylline-An immunomodulatory role in asthma?. Am. Rev. Respir. Dis. 147 (1993) 518-523
337. Weber B., Riess O., Hutchinson G., Collins C., Lin B.Y., Kowbel D., Andrew S., Schappert K., and Hayden M.R. Genomic organization and complete sequence of the human gene encoding the beta-subunit of the cGMP phosphodiesterase and its localisation to 4p 16.3. Nucleic Acids Res. 19 (1991) 6263-6268
338. Wright C.D., Kuipers P.J., Kobylarz Singer D., Devall L.J., Klinkefus B.A., and Weishaar R.E. Differential inhibition of human neutrophil functions. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase. Biochem. Pharmacol. 40 (1990) 699-707
339. Xiong Y., Westhead E.W., and Slakey L.L. Role of phosphodiesterase isoenzymes in regulating intracellular cyclic AMP in adenosine-stimulated smooth muscle cells. Biochem. J. 305 (1995) 627-633
340. Yukawa T., Kroegel C., Chanez P., Dent G., Ukena D., Chung K.F., and Barnes P.J. Effect of theophylline and adenosine on eosinophil function. Am. Rev. Respir. Dis. 140 (1989) 327-333
341. Zhang X., Robinson N.E., and Zhu F. Potentiation of acetylcholine release from tracheal parasympathetic nerves by cAMP. Am. J. Physiol. 270 (1996) L541-L546
342. Zocchi M.R., Pardi R., Gromo G., Ferrero E., Ferrero M.E., Besana C., and Rugarli C. Theophylline induced non specific suppressor activity in human peripheral blood lymphocytes. J. Immunopharmacol. 7 (1985) 217-234